Table 1

 Demographic data and baseline characteristics of study patients

nBosentan cohort(N = 139)nEpoprostenol cohort(N = 346)p value*
mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; SD, standard deviation.
*p values were determined using the Fisher’s exact test (sex) and the Student’s t test (all others).
†For most bosentan treated patients, time from diagnosis and haemodynamic data were available only at the start of the placebo controlled study.
Sex (M/F, %)13920/8034626/740.240
Age (years)
    Mean (SD)13946 (16)34141 (14)<0.001
Time from diagnosis of PAH to start of treatment (months)*
    Mean (SD)13832 (42)10013 (21)<0.001
Haemodynamics (mean (SD))†
    Cardiac index (l/min/m2)1382.4 (0.8)3172.0 (0.6)<0.001
    PVR (Wood units)13212 (6)20718 (10)<0.001
    mPAP (mm Hg)13956 (15)33366 (18)<0.001
    mRAP (mm Hg)1369 (5)33011 (5)<0.001
Walk test (m)
    Mean (SD)139351 (80)171335 (106)0.136